The complexity of atrial fibrillation newly diagnosed after ischemic stroke and transient ischemic attack: advances and uncertainties

Joshua O. Cerasuolo, Lauren E. Cipriano, and Luciano A. Sposato

Purpose of review
Atrial fibrillation is being increasingly diagnosed after ischemic stroke and transient ischemic attack (TIA). Patient characteristics, frequency and duration of paroxysms, and the risk of recurrent ischemic stroke associated with atrial fibrillation detected after stroke and TIA (AFDAS) may differ from atrial fibrillation already known before stroke occurrence. We aim to summarize major recent advances in the field, in the context of prior evidence, and to identify areas of uncertainty to be addressed in future research.

Recent findings
Half of all atrial fibrillations in ischemic stroke and TIA patients are AFDAS, and most of them are asymptomatic. Over 50% of AFDAS paroxysms last less than 30 s. The rapid initiation of cardiac monitoring and its duration are crucial for its timely and effective detection. AFDAS comprises a heterogeneous mix of atrial fibrillation, possibly including cardiogenic and neurogenic types, and a mix of both. Over 25 single markers and at least 10 scores have been proposed as predictors of AFDAS. However, there are considerable inconsistencies across studies. The role of AFDAS burden and its associated risk of stroke recurrence have not yet been investigated.

Summary
AFDAS may differ from atrial fibrillation known before stroke in several clinical dimensions, which are important for optimal patient care strategies. Many questions remain unanswered. Neurogenic and cardiogenic AFDAS need to be characterized, as it may be possible to avoid some neurogenic cases by initiating timely preventive treatments. AFDAS burden may differ in ischemic stroke and TIA patients, with distinctive diagnostic and treatment implications. The prognosis of AFDAS and its risk of recurrent stroke are still unknown; therefore, it is uncertain whether AFDAS patients should be treated with oral anticoagulants.

Keywords
atrial fibrillation, diagnosis, ischemic stroke, prevention, transient ischemic attack

INTRODUCTION
Increasing physicians’ awareness about atrial fibrillation and substantial improvements in cardiac monitoring technologies [1] have led to an increase in the number of patients diagnosed with atrial fibrillation after ischemic stroke and transient ischemic attack (TIA) [2]. Up to one-quarter of patients who are believed to be atrial fibrillation free before the stroke and subsequently undergo cardiac monitoring are newly diagnosed with atrial fibrillation [2]. After the diagnostic work-up of ischemic stroke and TIA patients, heart rhythm falls into three main categories: patients with previously known atrial fibrillation (KAF), atrial fibrillation newly detected after stroke and normal sinus rhythm (NSR). However, these three categories...
constitute an oversimplification, as some patients with atrial fibrillation newly detected after stroke had undiagnosed AF prior to the stroke and in others it is a new-onset arrhythmia (Fig. 1). Preexisting but newly diagnosed atrial fibrillation is most likely caused by prestroke cardiac structural changes, and thus, the arrhythmia could be considered as predominantly ‘cardiogenic’. Newly diagnosed atrial fibrillation may be the consequence of the stroke itself and therefore could be regarded as primarily ‘neurogenic’ [1,3]. Most likely, a considerable proportion of atrial fibrillation detected after stroke and TIA cases have a combination of cardiogenic and neurogenic mechanisms. Due to the intermittent nature of atrial fibrillation in some patients, many cases of atrial fibrillation in ischemic stroke and TIA patients may go undiagnosed without thorough screening [2]. This complexity explains the current lack of understanding of the pathophysiology of atrial fibrillation detected after stroke and why there are sizeable uncertainties regarding its

### KEY POINTS

- AFDAS comprises a heterogeneous mix of AF, possibly including cardiogenic and neurogenic types, and a mix of both.
- The current knowledge gaps about the significance of AFDAS should be acknowledged when deciding the best secondary preventive strategies.
- Much research is needed to clarify the risk of recurrent stroke and death associated with AFDAS, and to identify potential strategies aimed at preventing neurogenic types.
- AFDAS burden should be considered as a key target for future research, as it may help to better stratify stroke risk.
- Future research should target the prevention of AFDAS among ischemic stroke and TIA patients, and the reduction of the risk of atrial remodeling in those already diagnosed with AFDAS.

**FIGURE 1.** Apparent and actual heart rhythm before and after electrocardiographic monitoring in transient ischemic attack and ischemic stroke patients. AF, atrial fibrillation; cAF, cardiogenic atrial fibrillation; ECG, electrocardiographic; nAF, neurogenic atrial fibrillation; TIA, transient ischemic attack.
prognosis and suitable therapeutic approaches to prevent stroke recurrence.

NOMENCLATURE

Conceptually, atrial fibrillation detected after stroke is so complex that no currently used terminology fits adequately. ‘Poststroke AF’ implies that the atrial fibrillation is triggered by the stroke [1,2]. ‘Newly-diagnosed AF’ is not limited to atrial fibrillation diagnosed after a stroke or TIA. Indeed, it has been used for studies limited to stroke and TIA patients [4–6] as well as for nonselected cohorts [7]. ‘Occult AF’ [8] describes undiagnosed atrial fibrillation on any kind of patient, regardless of the patient’s stroke history. ‘Paroxysmal AF’ describes the intermittent nature of atrial fibrillation [9], but it does not differentiate between patients who are diagnosed before or after stroke.

We propose the term AFDAS for Atrial Fibrillation Detected (or Diagnosed) after Stroke or TIA. AFDAS comprises all cases of atrial fibrillation (paroxysmal, persistent or permanent) detected after ischemic stroke or TIA by any ECG monitoring technology. AFDAS includes atrial fibrillation that existed, but was undiagnosed, prior to the stroke as well as incident atrial fibrillation beginning near the time or shortly after the stroke event. pAFDAS can specifically indicate paroxysmal forms of AFDAS, as not all AFDAS are paroxysmal [5].

PATHOPHYSIOLOGY OF NEUROGENIC ATRIAL FIBRILLATION DETECTED AFTER STROKE AND TRANSIENT ISCHEMIC ATTACK

The pathophysiology of KAF, which is primarily cardiogenic, has been extensively investigated and research on this topic is continuously updated [10]. In comparison, little is known about the pathophysiology of AFDAS, in particular neurogenic AFDAS. As neurogenic AFDAS is a potential target for stroke prevention (e.g. preventing AFDAS triggered by strokes may help prevent recurrent events), we have proposed a hypothetical pathophysiological model involving autonomic and inflammatory pathways consistent with current evidence but requiring rigorous empirical investigation to validate (or invalidate) [1].

The autonomic regulation of cardiac rhythm can be conceptualized as an integrated relay system (Fig. 2). The highest level is represented by the cerebral cortex, particularly the insula, although other areas such as the cingulate and the prefrontal cortices are also implicated [11]. In turn, bilateral projections connect the right and left insular cortices with the hypothalamus, the limbic system and brainstem nuclei [11]. This higher component of the system is considered an overall ‘extrinsic’ or ‘cerebral’ regulation centre. The ‘intrinsic’ autonomic nervous system encompasses ganglionated plexi distributed along the ending of the pulmonary veins in the left atrium and within the pericardium [12]. This system is highly regulated by the extrinsic component [13]; thus, the loss of autonomic control mediated by damage to the insular cortex or its projections may result in AFDAS triggered at the ganglionated plexi. This concept is supported by current evidence: atrial fibrillation is triggered by focal firing of ganglionated plexi at pulmonary vein and nonpulmonary vein sites in the heart with high sensitivity to autonomic neurotransmission in up to 90% of the cases [1]; acute ischemia of the cerebral cortex, especially within the insula, generates major autonomic imbalances [14]; as shown by our group and others, the involvement of the insular cortex after ischemic stroke is more frequent among
patients with AFDAS than among those who remain in sinus rhythm [15–17].

Systemic inflammation also seems to play an important role in AFDAS generation by mechanisms comprising both focal firing (autonomic cascade) and re-entry circuits (atrial myocarditis) [1]. Focal firing at the ganglionic plexi could be initiated by poststroke systemic inflammation resulting in autonomic dysfunction [1]. A short-lasting inflammatory response including cytokines [e.g., interleukin (IL)-1 and IL-6], adhesion molecules (e.g., intercellular adhesion molecule-1 and E/P-selectins) and chemokines (e.g., CXCL16) released into the blood stream immediately follows acute ischemic stroke [18]. Furthermore, compared with other subtypes of ischemic stroke, patients with cardioembolic ischemic stroke have significantly higher plasma levels of tumour necrosis factor-alpha (TNF-α), IL-1β and IL-6 [19]. Interestingly, all these inflammatory markers have also been implicated in the genesis of atrial fibrillation [20] and have been shown to be related to autonomic imbalance [21]. In fact, elevated levels of IL-6 and C-reactive protein have been associated with decreased heart rate variability, a marker of autonomic dysfunction [21–23]. A prolonged inflammatory response can result in atrial remodeling and atrial fibrillation perpetuation through re-entry circuits, further contributing to the prothrombotic state of atrial fibrillation [1,20].

SCRENING FOR ATRIAL FIBRILLATION DETECTED AFTER STROKE AND TRANSIENT ISCHEMIC ATTACK: THE ROLE OF RAPID INITIATION AND DURATION OF CARDIAC MONITORING

Currently, there are several technologies available for atrial fibrillation screening after stroke for both in-hospital and ambulatory settings. The technologies vary significantly in their invasiveness from the perspective of the patient and the normal duration of monitoring. The most frequently used devices are conventional ECG, in-patient and out-patient telemetry, Holter monitoring, external loop recording and internal loop recording [2*,22]. Newly available self-monitoring devices and wearable technologies have shown promising results [24,25].

We recently estimated the atrial fibrillation detection yield for various inpatient and outpatient screening methods, separately and when used sequentially [2*,22]. Overall, we found that AFDAS can be detected in up to 23.7% of ischemic stroke and TIA patients without known atrial fibrillation by sequentially combining technologies [2*,22]. Considering that about 20% of ischemic stroke and TIA patients have KAF [26], we can estimate that approximately 40% (20 + 0.8 × 23.7) of patients with a history of stroke have atrial fibrillation, and that AFDAS accounts for half of all atrial fibrillation cases in patients with ischemic stroke and TIA.

Recent studies have struggled to compare the diagnostic yield of different technologies [27]. The lack of a gold standard has made these efforts challenging and has sometimes led to misleading conclusions [28]. Despite this limitation, the early initiation and the total duration of monitoring seem to be the most reliable determinants of AFDAS diagnostic yield [5,29].

The early initiation of cardiac monitoring is crucial for improving atrial fibrillation diagnosis after stroke and TIA, with over 70% of cases being diagnosed within the first 3 days after admission [5]. Furthermore, the odds of detecting AFDAS is over five-fold higher when continuous cardiac monitoring is initiated at a mean of 27 days after stroke than a mean of 75 days [2*,22]. It is unknown whether the higher atrial fibrillation diagnostic yield immediately after ischemic stroke and TIA is explained by a greater number or a longer duration of atrial fibrillation paroxysms. Regardless, delays in the initiation of cardiac monitoring after stroke may result in missed AFDAS paroxysms.

Up to 95% of atrial fibrillation paroxysms in patients with AFDAS are asymptomatic [5,30] and half of them last less than 30 s [31]. Not surprisingly, paroxysmal atrial fibrillation detection in ischemic stroke and TIA patients is highly determined by the duration of cardiac monitoring and atrial fibrillation burden. The latter is defined as the total time a patient spends in atrial fibrillation and is calculated by adding the duration of all atrial fibrillation paroxysms in a given period of cardiac monitoring (e.g., three paroxysms totaling 5.3 h of atrial fibrillation in 24 h of monitoring) [32*,22]. Two recent prospective studies have confirmed that prolonged cardiac monitoring results in substantial increases in the proportion of patients diagnosed with AFDAS [30,33]. Consistent with these findings, the American Heart Association recommendations support poststroke cardiac monitoring for up to 30 days [34]. However, the ideal sequence of technologies and the optimal duration of atrial fibrillation screening remain a matter of intense debate [8,35–43].

MARKERS OF ATRIAL FIBRILLATION DETECTED AFTER STROKE AND TRANSIENT ISCHEMIC ATTACK

The identification of patient characteristics for predicting AFDAS has become critical for the appropriate tailoring of monitoring allocation and duration.
such that patients with the highest odds of having atrial fibrillation are monitored for longer, whereas those who are at a low risk for atrial fibrillation are not subjected to unnecessary testing. As a result, in the recent years, there have been an overwhelming number of efforts to assess different candidate markers [6,44–61] and several scores [62–71] (HATCH, STAF, CHA2-DS2-Vasc, CHADS2, etc.) to improve the accuracy of AFDAS prediction.

Most recently identified markers comprise age [45,48,52,57,63,67,68]; female sex [6,67]; brain natriuretic peptide (BNP) [56,58,59,62,64]; troponin-I [53,60]; premature atrial complexes [44,52,54,55,61,72], prolonged PR interval [48] and QRS duration and total atrial conduction time [51] on ECG; preexisting heart disease or cardiac structural abnormalities (e.g. echocardiographic evidence of left atrial enlargement, left atrial function, impaired systolic function, left ventricular hypertrophy, mitral valve disease and epicardial fat) [6,44−47,52,62−65,68,69,73]; history of congestive heart failure [67] and coronary artery disease [57,68]; duration of stroke symptoms [57]; stroke severity [62,63,67]; prior cortical [50,65], anterior circulation [54], and posterior circulation [50] infarctions; white matter lesions [52], haemorrhagic transformation [45,65], susceptibility sign [65] and multiple infarcts [45] on brain MRI; and free fatty acid and triglyceride levels [65]. In patients with acute atrial fibrillation, there is depletion of lymphocytes, possibly due to excessive apoptosis mediated by inflammatory responses and decreased survival modulated by catecholamines [20]. As such, an increased neutrophil to lymphocyte ratio seems to predict incident and postprocedural atrial fibrillation; however, it has never been investigated as a marker of AFDAS to the best of our knowledge [74].

The large number of potential markers and the diversity of findings across studies reveal a great deal of remaining uncertainty. Inconsistency is due to methodological diversity, small study sample sizes limiting the adjustment of analyses for the multiple factors implicated in the genesis of atrial fibrillation and heterogeneity of AFDAS with regard to its pathophysiological mechanisms (e.g. cardiogenic vs. neurogenic). For instance, although classic markers of atrial fibrillation such as cardiac structural abnormalities would certainly predict cardiogenic AFDAS [6], their role, if any, in neurogenic AFDAS is controversial [15].

The search for biomarkers should not be limited to identifying patients at a higher risk of AFDAS. Other markers, such as specific characteristics of neurogenic AFDAS (e.g. autonomic dysfunction, strokes involving the insular cortex and lack of cardiac structural changes) [1] and predictors of cardiac remodeling (e.g. endothelin-1 and matrix metalloproteinase) [75–77] could be useful for identifying additional targets for the timely initiation of preventive strategies aimed at avoiding AFDAS perpetuation and stroke recurrence that could be tested in experimental studies (Fig. 3) [78–86]. Patients with acute neurogenic AFDAS may evolve to recurrent paroxysmal or even chronic or permanent AFDAS mediated by atrial remodeling, possibly representing a group at particularly high risk of recurrent stroke. Indeed, short paroxysmal episodes of atrial fibrillation can lead to atrial fibrillation perpetuation if they become recurrent through structural changes that take place in the atrial myocardium leading to remodeling [87–89]. The timely identification of patients at a higher risk of atrial remodeling may allow the rapid initiation of treatments aimed at preventing it.

ENDOTHELIAL DYSFUNCTION, ATRIAL FIBRILLATION DETECTED AFTER STROKE AND TRANSIENT ISCHEMIC ATTACK BURDEN, STROKE SEVERITY AND THE RISK OF STROKE RECURRENT

AFDAS burden very likely influences its detection. Little evidence on the relationship between AFDAS burden and stroke risk and severity is available. First, the existing literature focuses on patients with KAF. No study has investigated the relationship between atrial fibrillation burden and the risk of recurrence or stroke severity exclusively in the AFDAS population. Second, most data about atrial fibrillation burden and stroke risk are not generalizable because the study cohorts comprised highly selected populations with considerable heart disease (e.g. with pacemakers or implantable cardiac defibrillators) [32]. Third, current knowledge about the relationship between atrial fibrillation and cerebrovascular disease comes from studies based on single or a few ECGs used to detect atrial fibrillation before or/and after stroke [90]. The limitation of these studies is that short-duration monitoring, such as ECG, is more likely to detect high-burden atrial fibrillation, thus biasing the characteristics of the newly diagnosed atrial fibrillation population towards patients with highly recurrent or permanent/chronic atrial fibrillation. Furthermore, most studies have not considered paroxysms of less than 30 s as relevant in their analyses because of technical limitations. Interestingly, these episodes seem to be 10-fold more frequent than those more than 30 s when systematically screened by using 24-h Holter monitoring in patients with ischemic stroke of undetermined source [91]. This bias may have systematically influenced the atrial fibrillation
literature; therefore, shaping the current atrial fibrillation clinical paradigm with concepts such as ‘atrial fibrillation is more frequent in moderate/severe strokes than in minor strokes and TIAs’ [92], and ‘atrial fibrillation related ischemic strokes have worse outcomes and higher recurrence rates than most nonatrial fibrillation ischemic strokes’ [93,94].

In this context and with the availability of improved cardiac monitoring technologies, the relationship between paroxysmal atrial fibrillation and stroke needs to be revisited. Studies have shown that even a few hours of atrial fibrillation are enough to result in thrombus formation in the left atrium. Within the first 24 h and in the context of endothelial dysfunction, the left atrium undergoes remodeling shortly after paroxysmal atrial fibrillation onset resulting in a highly thrombogenic state [95]. Indeed, the endocardium of atrial fibrillation patients is highly prothrombotic and proinflammatory [96]. Atrial fibrillation itself stimulates platelet...
aggregation and coagulation mediated by beta-thromboglobulin [97], platelet factor 4 [98], von Willebrand factor [98] and increased expression of procoagulant genes [99] among other factors. On the basis of this evidence, we speculate that low-burden atrial fibrillation produces small thrombi, leading to minor strokes and TIsAs, whereas high-burden atrial fibrillation results in larger thrombi, causing more severe strokes (Fig. 4). This would explain, at least in part, why AFDAS is less frequently diagnosed among TIA and minor stroke patients compared with those including TIA and ischemic stroke participants (4% vs. 6.3–11.5%) [100]. These results may also be explained by our mechanistic hypothesis of neurogenic AFDAS generation, as after a TIA or minor stroke, there is only minimal structural brain damage, which could result in less severe dysautonomia and lower magnitude inflammatory responses, thus causing fewer ‘neurogenic’ AFDAS (Fig. 4) [15]. Accordingly, lower levels of BNP have been found in TIA patients than in those with ischemic stroke, potentially indicating a lesser impact of brain damage on cardiac function in TIA patients [101].

KNOWLEDGE GAPS AND FUTURE PERSPECTIVES

We have identified at least six major knowledge gaps regarding AFDAS:

FIGURE 4. Relationship between atrial fibrillation burden and stroke severity and recurrence. (a) Preexisting AF burden and its relationship with stroke severity and risk of recurrence. (b) Burden of AF detected after stroke and its relationship with stroke severity and risk of recurrence. Turquoise boxes: potential diagnostic and prognostic consequences of AF burden. Grey: thrombus and infarct size (a) or infarct size and associated pathophysiological mechanisms (b).
(1) The characterization of neurogenic and cardio- 
 genic AFDAS;  
(2) How and when neurogenic atrial fibrillation is 
  triggered;  
(3) The identification of reliable markers to predict 
  atrial fibrillation in patients with recent stroke 
  and no history of atrial fibrillation, as well as 
  predictors of atrial fibrillation perpetuation and 
  stroke recurrence in patients with AFDAS;  
(4) The effect of KAF and AFDAS burden on stroke 
  severity and recurrence;  
(5) Whether the risk of AFDAS in terms of stroke 
  recurrence and death warrants the use of oral 
  anticoagulants. There is general expert agree- 
  ment in that AFDAS patients should be started 
  on oral anticoagulants to prevent stroke and 
  systemic embolism [2]. As such, most patients 
  with AFDAS are treated with oral anticoagulants 
  [102]. However, the expert agreement relies 
  largely on what is known about atrial fibrilla- 
  tion diagnosed prior to stroke, which may 
  disproportionately be symptomatic, higher 
  burden or occurring in patients with con- 
  comitant illnesses that made their atrial fibrilla- 
  tion diagnosis more likely (such as other 
  forms of heart disease). Patients with AFDAS 
  may have a lower risk of recurrent stroke and 
  their recurrent strokes may be less severe com- 
  pared with patients with KAF. If this is true, 
  their risk–benefit profile for oral anticoagulants 
  may be different, and thus, specifically tailored 
  risk stratification may be necessary to facilitate 
  patient-centred care.  
(6) The role of AFDAS as a mechanism of emboliza-
  tion. AFDAS could be just a marker of endo-
  thelial dysfunction, atrial hypercoagulability and 
  increased risk of embolism, but not the 
  embolizing mechanism itself [10]. Endothelial 
  dysfunction and atrial hypercoagulability are 
  consequences of vascular risk factors and age, 
  which could be acutely enhanced by ischemic 
  strokes involving the insula, leading to substan-
  tial changes in cardiac structure, such as sub-
  endocardial haemorrhage, ischemic damage 
  and subendocardial oedema [103].

Ongoing studies such as Detection of Silent 
Atrial Fibrillation after Ischemic StrOke (SAFFO) 
[104], Impact of Standardized Monitoring for 
Detection of Atrial Fibrillation in Ischemic Stroke 
(MonDAFIS) [105], Finding Atrial Fibrillation in 
stroke patients – Randomized (Find-AF Random-
ized) [106], Detection of occult paroxysmal atrial 
fibrillation by implantable long-term ECG monitor-
ing in cryptogenic stroke and TIA [107] and PAt-
ophysiology and Risk of Atrial fibrillation Detected 
after Ischemic Stroke (PARADISE) will probably 
address many of the currently unknown aspects 
of AFDAS.

CONCLUSION

New cardiac monitoring technologies have 
dramatically improved the detection of atrial fibril-
lation in stroke and TIA patients revealing a large 
number of patients whose atrial fibrillation progno-
isis may not be well understood. Ongoing research 
will fill in some of the gaps. Improved understand-
ing of neurogenic atrial fibrillation may contribute 
to a broader understanding of the heart and brain 
connection and of neurogenic causes of cardiac 
arrhythmias. Furthermore, the rapid integration of 
new knowledge about AFDAS into patient-centred 
care will improve the selective use of long-term 
monitoring and will help to tailor treatment regi-
mens to patient risk profiles, ultimately improving 
health outcomes.

Acknowledgements
We especially thank Maryse Paquet, PhD, CCRP, for her 
significant contributions to the contents of this manu-
script and for her thorough and comprehensive input. We 
thank Emma Vought for the design of the figures.

Financial support and sponsorship
None.

Conflicts of interest
L.A. Sposato has received research funds and speaker 
honoraria from Boehringer Ingelheim. L.A. Sposato is 
supported by the Edward and Alma Saraydar Neuro-
sciences Fund and by the Opportunities Fund of the 
Academic Health Sciences Centre Alternative Funding 
Plan of the Academic Medical Organization of South-
western Ontario (AMOSO). L.E. Cipriano is supported by 
the Natural Sciences and Engineering Council of Canada 
(NSERC). For J.O. Cerasuolo there are no conflicts of 
interest.

REFERENCES AND RECOMMENDED 
READING
Papers of particular interest, published within the annual period of review, have 
been highlighted as:  
* of special interest  
** of outstanding interest

1. Sposato LA, Riccio PM, Hachinski VH. Poststroke atrial fibrillation: cause or 
consequence? Critical review of current views. Neurology 2014; 82:1180– 
1186.  
2. Sposato LA, Cipriano LE, Saposnik G, et al. Diagnosis of atrial fibrillation after 
stroke and transient ischaemic attack: a systematic review and meta-analysis. 
Lancet Neurol 2015; 14:377–387. This publication analyzed the diagnostic yield of each cardiac monitoring both 
individually and combined sequentially, showing that over half of overall atrial 
fibrillation in stroke and TIA patients are diagnosed after the stroke. The need of 
thorough monitoring is highlighted.
Cerebrovascular disease

3. Seifert F, Kallmunzer B, Gutjahr I, et al. Neuroanatomical correlates of severe cardiac arrhythmias in acute ischemic stroke. J Neurol 2015; 262: 1182–1190.

4. Riccio PM, Klein FR, Pagani Cassara F, et al. Newly diagnosed atrial fibrillation linked to wake-up stroke and TIA: hypothetical implications. Neurology 2013; 80:1834–1840.

5. Sposato LA, Klein FR, Jauregui A, et al. Newly diagnosed atrial fibrillation after acute ischaemic stroke and transient ischaemic attack: importance of immediate and prolonged continuous cardiac monitoring. J Stroke Cerebrovasc Dis 2012; 21:210–216.

6. Rizos T, Hornsman S, Ditten F, et al. Pre-existing heart disease underlies newly diagnosed atrial fibrillation after acute ischaemic stroke. Stroke 2016; 47:330–341.

7. Bassand JP, Accocia G, Camm AJ, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J 2016. [Epub ahead of print]

8. Andrade JG, Field T, Khayat P. Detection of occult atrial fibrillation in patients with embolic stroke of uncertain source: a work in progress. Front Physiol 2015; 6:100.

9. Rizos T, Quiltzsch A, Busse O, et al. Diagnostic work-up for detection of paroxysmal atrial fibrillation after acute stroke: cross-sectional survey on German stroke units. Stroke 2015; 46:1693–1695.

10. Kamel H, Okin PM, Eikinda MS, ladeoca C. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke 2016; 47:895–900.

11. Oppenheimer SM, Cecchetto DF, Hachinski VC. Cerebrogenic cardiac arrhythmias. Cerebral electrocardiographic influences and their role in sudden death. Adv Neurol 1980; 37:513–519.

12. Amour JA, Murphy DA, Yuan BX, et al. Gross and microscopic anatomy of the human intrinsic cardiac nervous system. Anat Rec 1997; 247:269–298.

13. Park HW, Shen MJ, Lin SF, et al. Neural mechanisms of atrial fibrillation. Nat Rev Cardiol 2015; 12:90–30.

14. Cecchetto DF, Wilson JX, Smith KE, et al. Autonomic and myocardial changes in minor cerebral arterial occlusion: stroke models in the rat. Brain Res 1989; 502:296–305.

15. Gonzalez Toledo ME, Klein FR, Riccio PM, et al. Atrial fibrillation detected after acute ischaemic stroke: evidence supporting the neurogenic hypothesis. J Stroke Cerebrovasc Dis 2013; 22:e486–e491.

16. Frontzek K, Fluri F, Siemeruk J, et al. Isolated insular strokes and plasma MR-proANP levels are associated with newly diagnosed atrial fibrillation: a pilot study. PLoS One 2014; 9:e92421.

17. Scheitz JF, Erdur H, Haeusler KG, et al. Excessive supraventricular ectopic activity is indicative of paroxysmal atrial fibrillation in patients with cerebral ischemia – the Find-AF pilot study. PLoS One 2014; 9:e92421.

18. Choe WC, Passman RS, Brachmann J, et al. A comparison of atrial fibrillation monitoring strategies after cryptogenic stroke (from the Cryptogenic Stroke and Underlying AF Trial). Am J Cardiol 2015; 116:889–893.

19. Cipriano LE, Sposato LA. Estimating the sensitivity of holter to detect atrial fibrillation after stroke or transient ischaemic attack without a gold standard is challenging. Am J Cardiol 2016; 117:314–316.

20. Kishore AR, Sindhi A, Majid A, et al. Detection of atrial fibrillation after ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis. Stroke 2014; 45:520–526.

21. Sanna D, Dinner HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. New Eng J Med 2014; 370:2478–2486.
57. Wohlfahrt J, Stahrenberg R, Weber-Kruger M, et al. Clinical predictors to identify paroxysmal atrial fibrillation after ischemic stroke. Eur J Neurol 2014; 21:21–27.

58. Shibazaki K, Kimura K, Fujii S, et al. Brain natriuretic peptide levels as a predictor for new atrial fibrillation during hospitalization in patients with acute ischemic stroke. Am J Cardiol 2012; 109:1303–1307.

59. Suissa S, Bremond S, Lachaud S, Mahagne MH. Brain natriuretic peptide: a relevant marker to rule out delayed atrial fibrillation in stroke patient. J Stroke Cerebrovasc Dis 2013; 22:e103–e110.

60. Lasek-Bal A, Gaster Z, Kowalewska-Twardela T, Urbanek T. New-onset atrial fibrillation in patients with elevated troponin I levels in the acute phase of stroke. Int J Cardiol 2015; 195:210–211.

61. Gladstone DJ, Dorian P, Spring M, et al. Atrial premature beats predict atrial fibrillation in cryptogenic stroke: results from the EMBRACE trial. Stroke 2015; 46:936–941.

62. Fuji S, Shibazaki K, Kimura K, et al. A simple score for predicting paroxysmal atrial fibrillation in acute ischemic stroke. J Neurol Sci 2013; 328:83–86.

63. Figueroedo MM, Rodrigues AC, Alves MB, et al. Score for atrial fibrillation detection in acute stroke and transient ischemic attack patients in a Brazilian population: the acute stroke atrial fibrillation scoring system. Clinics (Sao Paulo) 2014; 69:241–246.

64. Yoshiosa K, Watanabe K, Zeniya S, et al. A score for predicting paroxysmal atrial fibrillation in acute stroke patients: IPAB score. J Stroke Cerebrovasc Dis 2015; 24:263–269.

65. Seo WK, SH, Jung K, et al. Novel composite score to predict atrial fibrillation in acute stroke patients: AP predicting score in acute stroke. Int J Cardiol 2012; 162:184–189.

66. Faucher L, Clementy N, Pelade C, et al. Patients With ischemic stroke and incident atrial fibrillation: a nationwide cohort study. Stroke 2015; 46:2432–2437.

67. Giralte-Stenhaus E, Cuadrado-Godia E, Soniano-Tarraga C, et al. New-onset paroxysmal atrial fibrillation diagnosis in ischemic stroke patients. Eur Neurol 2015; 74:241–247.

68. Bugnicourt JM, Flamant M, Guillamp MT, et al. Predictors of newly diagnosed atrial fibrillation in cryptogenic stroke: a cohort study. Eur J Neurol 2013; 20:1352–1359.

69. Chen K, Bai R, Deng W, et al. HATCH score in the prediction of new-onset atrial fibrillation after catheter ablation of typical atrial flutter. Heart Rhythm 2015; 12:1483–1489.

70. Baturova MA, Lindgren A, Carlson J, et al. Predictors of new onset atrial fibrillation during 10-year follow-up after first-ever ischemic stroke. Int J Cardiol 2015; 199:248–252.

71. Suissa L, Mahagne MH, Lachaud S. Score for the targeting of atrial fibrillation: a new approach to diagnosing paroxysmal atrial fibrillation. Cerebrovasc Dis 2011; 31:442–447.

72. Vinther KH, Teskow C, Moller S, et al. Prevalence and prognostic significance of runs of premature atrial complexes in ischemic stroke patients. J Stroke Cerebrovasc Dis 2016; 25:2338–2343.

73. Gutierrez A, Van Wagoner DR. Oxidant and inflammatory mechanisms and targeted therapy in atrial fibrillation: an update. J Cardiovasc Pharmacol Ther 2015; 20:523–529.

74. This publication reviews innovative approaches for the treatment and prevention of atrial fibrillation: targeting inflammation and oxidative stress.

75. Shao Q, Chen K, Rha SW, et al. Usefulness of neutrophil/lymphocyte ratio as a predictor of atrial fibrillation: a meta-analysis. Arch Med Res 2015; 46:189–198.

76. Nakazawa Y, Ashihara T, Tsutamoto T, et al. endothelin-1 as a predictor of atrial fibrillation recurrence after pulmonary vein isolation. Heart Rhythm 2009; 6:725–730.

77. Anne W, Willems R, Roskams T, et al. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation. Cardiovasc Res 2005; 67:655–666.

78. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol 2014; 63:2335–2345.

79. Dieleman JM, van Paassen J, van Dijk D, et al. Prophylactic corticosteroids for cardio pulmonary bypass in adults. Cochrane Database Syst Rev 2011; (5):CD005566.

80. Aschauer-Sobbi R, Izaddoustdar F, Korogyi AS, et al. Increased atrial arrhythmia susceptibility induced by intense endurance exercise in mice requires TNP-alpha. Nat Commun 2015; 6:6018.

81. Rezaei Y, Gholami-Fesharaki M, Dehghani MR, et al. Statin antiarrhythmic effect on atrial fibrillation in statin-naive patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther 2017; 21:197–176.

82. Ji T, Feng C, Sun L, et al. Are beta-blockers effective for preventing post-coronary artery bypass grafting atrial fibrillation? Direct and network meta-analyses. Ir J Med Sci 2016; 185:503–511.

83. Namas W, Arakien JC, Paana T, Karjalainen PP. Renal sympathetic denervation for treatment of patients with atrial fibrillation: Reappraisal of the available evidence. Heart Rhythm 2016.

84. Liu T, Korantzopoulos P, Shao G, et al. Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis. Euroace 2016; 18:672–678.